LLY

1,024.93

+1.7%↑

JNJ

211.32

+0.84%↑

ABBV

222.39

-0.23%↓

UNH

341.33

+1.48%↑

AZN

89.83

-0.92%↓

LLY

1,024.93

+1.7%↑

JNJ

211.32

+0.84%↑

ABBV

222.39

-0.23%↓

UNH

341.33

+1.48%↑

AZN

89.83

-0.92%↓

LLY

1,024.93

+1.7%↑

JNJ

211.32

+0.84%↑

ABBV

222.39

-0.23%↓

UNH

341.33

+1.48%↑

AZN

89.83

-0.92%↓

LLY

1,024.93

+1.7%↑

JNJ

211.32

+0.84%↑

ABBV

222.39

-0.23%↓

UNH

341.33

+1.48%↑

AZN

89.83

-0.92%↓

LLY

1,024.93

+1.7%↑

JNJ

211.32

+0.84%↑

ABBV

222.39

-0.23%↓

UNH

341.33

+1.48%↑

AZN

89.83

-0.92%↓

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

43.87 -0.05

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

43.13

Максимум

44.07

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	4M -90M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+26.52% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	211M 3.4B
Предишно отваряне	43.92
Предишно затваряне	43.87

Настроения в новините

By Acuity

25%

75%

68 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.12.2025 г., 23:58 ч. UTC

Придобивния, сливания и поглъщания

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11.12.2025 г., 23:56 ч. UTC

Печалби

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11.12.2025 г., 23:03 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11.12.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11.12.2025 г., 21:50 ч. UTC

Печалби

Costco Same-Store Sales, Membership Fees Rose in 1Q

11.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

11.12.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11.12.2025 г., 23:37 ч. UTC

Пазарно говорене

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11.12.2025 г., 23:31 ч. UTC

Печалби

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11.12.2025 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11.12.2025 г., 22:35 ч. UTC

Печалби

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11.12.2025 г., 22:30 ч. UTC

Печалби

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11.12.2025 г., 22:09 ч. UTC

Придобивния, сливания и поглъщания

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11.12.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11.12.2025 г., 22:05 ч. UTC

Печалби

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11.12.2025 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

11.12.2025 г., 21:39 ч. UTC

Печалби

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11.12.2025 г., 21:39 ч. UTC

Печалби

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11.12.2025 г., 21:38 ч. UTC

Печалби

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11.12.2025 г., 21:37 ч. UTC

Печалби

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11.12.2025 г., 21:37 ч. UTC

Пазарно говорене

Broadcom Sees AI Revenue Doubling -- Market Talk

11.12.2025 г., 21:34 ч. UTC

Придобивния, сливания и поглъщания

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11.12.2025 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

Dexus Aiming for Long-Term Holding of A$50M in Fund

11.12.2025 г., 21:28 ч. UTC

Пазарно говорене

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Dexus: Third Party Investors to Contribute Remainder

11.12.2025 г., 21:27 ч. UTC

Придобивния, сливания и поглъщания

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11.12.2025 г., 21:26 ч. UTC

Придобивния, сливания и поглъщания

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11.12.2025 г., 21:25 ч. UTC

Придобивния, сливания и поглъщания

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

26.52% нагоре

12-месечна прогноза

Среден 54.96 USD 26.52%

Висок 65 USD

Нисък 44 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

15 ratings

Купи

Задържане

Продай

Според 15 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

68 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.